A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

Inclusion criteria

• . Be a female between 18 to 45 years of age.
• . Have at least one well defined dimple that is at least 1 cm but not more than 2 cm along the long axis and that is evident when the subject is standing
• . Have a photonumeric cellulite severity scale (CSS) score between 6 and 12
• . Have a Body Mass Index (BMI) \>19 and \<30 kg/m2, and intends to maintain stable body weight throughout the duration of the study
• . Be willing to apply appropriate sunscreen to the selected quadrant before each exposure to the sun while participating in the study
• . Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening.
• . Have a negative urine pregnancy test at screening and before injection of AA4500 and be using an effective contraception method (ie, abstinence, intrauterine device \[IUD\], hormonal \[estrogen/progestin\] contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for the duration of the study.
• . Be willing and able to cooperate with the requirements of the study.

Exclusion criteria